Laboratory reconstitution principles

The educational scope of this guide

Every compound page on this site that describes a lyophilized peptide includes a reconstitution section describing how the lyophilized powder in a research-supply or compounded vial gets prepared for use. Those individual sections describe the specifics of that particular compound. This guide covers the shared conceptual foundation that all of those sections assume. It is not a recommendation to reconstitute or use any compound — most of the peptides on this site are not approved as therapeutic drugs, and reconstituting them for research use is a technical activity that requires appropriate context. What this guide can do is explain the general principles so that when you read a compound page's reconstitution section, the concepts of vial mass, diluent choice, target concentration and injection volume make coherent sense together.

Vial mass versus concentration versus injection dose

The three quantities that get confused most often in peptide reconstitution are the vial mass (how much peptide, in milligrams, is in the whole vial), the resulting concentration after reconstitution (how many milligrams of peptide per millilitre of solution), and the injection dose (how many milligrams delivered per injection). These are not the same number and they answer different questions. A 5 mg vial reconstituted with 2 mL of bacteriostatic water produces a solution at 2.5 mg/mL. An injection volume of 0.2 mL from that solution delivers 0.5 mg of peptide. Confusing any of these three produces dosing errors — most commonly ten-fold errors when the concentration and injection volume are mixed up. The reference formula that every compound page uses is: final concentration (mg/mL) = vial mass (mg) ÷ diluent volume (mL). Once concentration is known, injection dose = injection volume × concentration.

Why the diluent choice matters

Different diluents serve different purposes and have different implications for peptide stability and injection tolerability. Bacteriostatic water for injection (BAC water) is water containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol allows the vial to be accessed multiple times over an extended period without bacterial contamination in the vial itself — the standard peptide-therapy convention because most research-supply peptides are packaged in multi-dose vials. Sterile saline (0.9% sodium chloride) contains no preservative and is preferred for single-use preparations, intranasal delivery where nasal mucosa is more sensitive to preservatives, and any context where benzyl alcohol tolerability is a concern. Sterile water for injection (without preservative) is a third option, but its lack of preservative and lack of tonicity match to blood makes it inappropriate for most subcutaneous use cases. Some peptides also have specific stability considerations that dictate diluent — pH-buffered formulations for NAD+, for example, exist because non-buffered NAD+ produces injection-site pain from non-physiological pH.

Why you swirl and do not shake

Every reconstitution instruction says to swirl or roll the vial gently rather than shake it. This is not superstition. Vigorous shaking of a peptide solution produces foam through the air-liquid interface, and that interface is where partially-folded peptides are most likely to unfold, aggregate, and lose activity. Peptide degradation via air-liquid interface exposure is a well-characterised failure mode in peptide manufacturing. Gentle swirling brings the diluent into contact with the powder without generating foam, allowing complete dissolution without denaturation. Directing the diluent stream down the vial wall rather than onto the powder directly is another element of the same principle — a hard stream of liquid onto lyophilized powder produces local turbulence and foam risk. The technique is worth respecting as a general practice.

Verification, labelling, and beyond-use dating

Every compound page emphasises verifying the labelled peptide mass, diluent, and beyond-use date with the dispensing source before starting a reconstitution. This is the piece that distinguishes a laboratory-grade practice from an ad-hoc one. Research-supply peptides come from suppliers of varying quality; identity, mass and sterility are supplier-dependent rather than assumed. Vials with tampered seals, discoloured contents, or unclear labelling should not be used regardless of how much they cost. Once reconstituted, the vial should be labelled with the date of reconstitution, the peptide identity, the calculated concentration, and the beyond-use date after which the solution is considered no longer safe to use. Different peptides have different stability in solution — some are stable at refrigerator temperature for several weeks, some for only days. The supplier's documentation is the authoritative source; the reference values on each compound page are typical rather than compound-specific guarantees.

Before starting any reconstitution

• 1

  Verify the labelled peptide identity and mass from the dispensing source documentation.

• 2

  Confirm the intended diluent (bacteriostatic water, sterile saline, or a specific buffer if the peptide requires it).

• 3

  Calculate the target final concentration from labelled mass and specified diluent volume before you begin.

• 4

  Inspect the vial for damage, tampering, or visibly abnormal contents.

• 5

  Use clean aseptic technique — wash hands, disinfect the work surface, use sterile disposables, alcohol-swab all vial stoppers.

• 6

  Direct the diluent down the vial wall, not directly onto the lyophilized powder.

• 7

  Swirl or roll the vial gently until fully dissolved and clear. Do not shake.

• 8

  Label the reconstituted vial with date, peptide identity, concentration, and beyond-use date before storing.

• 9

  Do not proceed if any parameter cannot be verified. The vial should not be used.

Common questions

References

• BPC 157 and Standard Angiogenic Growth Factors — Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing· Seiwerth S, Milavic M, Vukojevic J, et al. · 2019

Links open external, peer-reviewed sources. Healthy Mango does not host trial data.